What is Jiangsu Recbio Technology's current stock price?

Jiangsu Recbio Technology's stock last closed at HK$5.5 on the Hong Kong Stock Exchange, with no change from its previous closing price. For more details, visit 2179.HK .

Why is Jiangsu Recbio Technology considered oversold?

The company’s stock has a Relative Strength Index (RSI) of 17.89, indicating it's oversold and may experience a potential bounce, particularly as technical indicators suggest strong downward pressure.

What are the main risks associated with Jiangsu Recbio’s stock?

The main risks include financial instability, indicated by negative EPS and high debt-to-equity ratio, along with uncertainties surrounding clinical trial outcomes.

How does Jiangsu Recbio plan to improve its financial health?

The company is focusing on advancing its vaccine R&D pipeline, including several promising candidates in various trial stages that could enhance its revenues upon successful commercialization.

What are the future price targets for Jiangsu Recbio?

Analyst forecasts vary, with medium to long-term targets suggesting HK$6.04 to HK$9.07, contingent on successful trials and market conditions. Meyka AI provides ongoing analysis in this sector.

HK Stocks

Jiangsu Recbio Technology Co., Ltd.: Navigating Challenging Waters with Promising Vaccine Developments

ByHuzaifa Zahoor December 15, 2025December 15, 2025

Jiangsu Recbio Technology Co., Ltd. (2179.HK) finds itself at a critical juncture. Currently trading at HK$5.5 on the Hong Kong Stock Exchange, the company’s stock shows zero change from its previous close despite a challenging six-month decline of 29.61%. As a key player in the biotechnology sector, particularly in vaccine development, the company’s performance is being closely monitored by investors and analysts alike.